Amiodarone - sanofi-aventis

Drug Profile

Amiodarone - sanofi-aventis

Alternative Names: Amiodarone IV; Ancaron

Latest Information Update: 17 Mar 2009

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Taisho Pharmaceutical
  • Developer Sanofi
  • Class Benzofurans; Class III antiarrhythmics; Heart failure therapies; Small molecules
  • Mechanism of Action Beta-adrenergic receptor antagonists; Calcium channel antagonists; KATP channel inhibitors; Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Atrial fibrillation

Highest Development Phases

  • Marketed Ventricular arrhythmias

Most Recent Events

  • 29 Apr 2016 Biomarkers information updated
  • 05 Sep 2007 Data presented at the European Society of Cardiology Congress 2007 (ESC-2007) added to the Arrhythmias pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top